Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

TIKATA 60 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/TIKATA 60 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG

Approved

STANDARD

TIKATA 60 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG

Adamed Laboratorios S.L.U.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: May 13, 2024
Approval ID: 45e541e3365a4be0
Company: Adamed Laboratorios S.L.U.
Type: Standard

Approval Details

Approval Id: 45e541e3365a4be0
Drug Cima Aemps Name: TIKATA 60 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG
Register Number: 89560
Holder Company Name: Adamed Laboratorios S.L.U.
Marketing Company Name: Adamed Laboratorios S.L.U.
Authorization Date: 2024-05-13
Dosage Form: COMPRIMIDO RECUBIERTO CON PELÍCULA
Dose: 60 mg
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: No
Company Name: Adamed Laboratorios S.L.U.

Active Ingredients

TICAGRELOR

60 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

May 13, 2024

Approval ID

45e541e3365a4be0

Type

Standard

Back to CIMA-AEMPS Approvals